688202
vs
S
Shanghai Composite
688202
Over the past 12 months, Shanghai Medicilon Inc has significantly outperformed Shanghai Composite, delivering a return of +74% compared to the Shanghai Composite's +22% growth.
Stocks Performance
688202 vs Shanghai Composite
Performance Gap
688202 vs Shanghai Composite
Performance By Year
688202 vs Shanghai Composite
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Shanghai Medicilon Inc
Glance View
Shanghai Medicilon, Inc. provides outsourced research and development services for pharmaceutical and biotechnology companies through contractual forms. The company is headquartered in Shanghai, Shanghai and currently employs 2,440 full-time employees. The company went IPO on 2019-11-05. The firm is committed to providing a full range of new drug research and development (R&D) services for pharmaceutical enterprises and other new drug R&D institutions. The firm's main businesses include drug discovery and pharmaceutical research and preclinical research. The drug discovery and pharmaceutical research mainly include services such as compound synthesis and screening, active pharmaceutical ingredients (API) and preparation technology research. The preclinical research services mainly include pharmacodynamics research, pharmacokinetics research, toxicology research and other services. The firm provides services for domestic and foreign customers such as the United States, Europe, Japan and South Korea.
